et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J. Clin. Invest. 108, 1429–1437 (2001). This shows that statin therapy suppresses hypertrophy coupled to the inhibition of GTP binding to RhoA and RAC1. CAS PubMed PubMed Central Google Scholar Dechend, R. ...
Small mole- cule therapy for managing moderate to severe pso- riatic arthritis. Expert Opin Pharmacother. 2017;18:1557-67.Costa L, Del Puente A, Peluso R, et al. Small molecule therapy for managing moderate to severe psoriatic arthritis. Expert Opin Pharmacother 2017;18:1557-67....
Tuberculosis remains the biggest infectious threat to humanity with one-third of the population infected and 1.4 million deaths and 8.7 million new cases annually. Current tuberculosis therapy is lengthy and consists of multiple antimicrobials, which causes poor compliance and high treatment dropout, resu...
Lung cancer patients with KRAS mutation(s) have a poor prognosis due in part to the development of resistance to currently available therapeutic interventions. Development of a new class of anticancer agents that directly targets KRAS may provide a more
Hence, targeting SHP2 might significantly potentiate PD-1/PD-L1 blockade therapy. Several small-molecule SHP2 inhibitors have shown immuno-boosting activities [92,98]. Hao et al. reported the synergistic effect of the first clinically-tested allosteric SHP2 inhibitor—TNO155—with the PD-L1 ...
Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases This invention provides various combinations of enzyme replacement therapy, gene therapy, and small molecule therapy for the treatment of lysosomal storage diseases. D Meeker,SH Cheng - WO 被引量: 74...
A novel small molecule chaperone of rod opsin and its potential therapy for retinal degeneration Abstract Rhodopsin homeostasis is tightly coupled to rod photoreceptor cell survival and vision. Mutations resulting in the misfolding of rhodopsin can lead to autosomal dominant retinitis pigmentosa (adRP),...
Small Molecule Drug Therapeutic Technology and Methodology / Therapy / Small Molecule DrugTherapeutic Technology and Methodology / Therapy / Small Molecule DrugDiscovery Medicine
In recent years, neurological disorders have globally become a leading cause of disability and death. Neurological disorders are very common in both high-
Metabolic abnormalities lead to the dysfunction of metabolic pathways and metabolite accumulation or deficiency which is well-recognized hallmarks of diseases. Metabolite signatures that have close proximity to subject’s phenotypic informative dimension